For all the trials involving T‐DM1, the population enrolled included HER2‐positive metastatic breast cancer, while for T‐DXd one trial accrued patients with HER2‐positive metastatic disease while two trials HER2‐low/ultralow metastatic breast cancer. This evidence concerns the gene ERBB2 and metastatic neoplasm.